Enhanced surveillance at Uvira's two cholera treatment facilities ran from 2017 to 2023, around a 2020 campaign that reached 66% with at least one dose. Counterfactual transmission modelling estimated that the campaign averted 56% of infections and deaths over three years. This corresponds to a median of 2,350 averted facility-attended cases and 44 averted deaths.
Why it is interesting: A population-level estimate of oral cholera vaccine impact in an endemic African city, where evidence has been limited.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.